DnB Asset Management
NBIX icon

DnB Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

DnB Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.3M Sell
120,337
-20,895
-15% -$3.1M 0.06% 214
2026
Q1 		$18.6M Buy
141,232
+1,775
+1% +$236K 0.07% 193
2025
Q4 		$19.8M Buy
139,457
+15,349
+12% +$2.22M 0.07% 186
2025
Q3 		$17.4M Buy
124,108
+9,168
+8% +$1.24M 0.07% 204
2025
Q2 		$14.4M Sell
114,940
-13,172
-10% -$1.51M 0.06% 209
2025
Q1 		$14.2M Buy
128,112
+9,885
+8% +$1.25M 0.07% 200
2024
Q4 		$16.1M Buy
118,227
+3,500
+3% +$433K 0.07% 194
2024
Q3 		$13.2M Buy
114,727
+39,781
+53% +$5.45M 0.06% 214
2024
Q2 		$10.3M Buy
74,946
+10,998
+17% +$1.51M 0.05% 220
2024
Q1 		$8.82M Sell
63,948
-1,895
-3% -$259K 0.05% 243
2023
Q4 		$8.68M Sell
65,843
-14,189
-18% -$1.63M 0.05% 265
2023
Q3 		$9M Sell
80,032
-3,645
-4% -$384K 0.05% 246
2023
Q2 		$7.89M Sell
83,677
-12,440
-13% -$1.22M 0.05% 279
2023
Q1 		$9.73M Buy
96,117
+9,456
+11% +$984K 0.06% 239
2022
Q4 		$10.4M Sell
86,661
-1,105
-1% -$129K 0.07% 214
2022
Q3 		$9.32M Sell
87,766
-38,559
-31% -$3.91M 0.07% 221
2022
Q2 		$12.3M Sell
126,325
-8,829
-7% -$815K 0.09% 195
2022
Q1 		$12.7M Sell
135,154
-5,469
-4% -$463K 0.08% 205
2021
Q4 		$12M Buy
140,623
+22,344
+19% +$2.06M 0.07% 208
2021
Q3 		$11.3M Sell
118,279
-19,944
-14% -$1.88M 0.07% 208
2021
Q2 		$13.5M Buy
138,223
+19,454
+16% +$1.86M 0.09% 178
2021
Q1 		$11.6M Buy
118,769
+83,562
+237% +$8.76M 0.08% 187
2020
Q4 		$3.37M Buy
35,207
+22,831
+184% +$2.21M 0.03% 353
2020
Q3 		$1.19M Hold
12,376
– – 0.01% 505
2020
Q2 		$1.51M Buy
12,376
+1,477
+14% +$163K 0.02% 434
2020
Q1 		$943K Sell
10,899
-930
-8% -$91K 0.01% 493
2019
Q4 		$1.27M Buy
+11,829
New +$1.24M 0.01% 544

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

DnB Asset Management's NBIX Position: Q2 2026 in Review

DnB Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 15% in Q2 2026, selling an estimated $3.1M and leaving 120,337 shares worth $20.3M. The position accounts for 0.06% of the portfolio, ranked #214.

DnB Asset Management first reported a position in NBIX in Q4 2019 and has held it in 27 quarters since. 473 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • DnB Asset Management held 120,337 shares of Neurocrine Biosciences worth $20.3M as of Q2 2026.
  • DnB Asset Management sold 20,895 Neurocrine Biosciences shares in Q2 2026, an estimated $3.1M.
  • Neurocrine Biosciences made up 0.06% of DnB Asset Management's portfolio in Q2 2026, its #214 holding.
  • DnB Asset Management first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 27 quarters since.
  • 473 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.